Treatment patterns appear to be similar for medullary thyroid carcinoma (MTC) patients with and without REarranged during Transfection (RET) mutations, according to a poster presented at the European Society for Medical Oncology (ESMO) Congress 2021.

“Surgery and adjuvant [treatment] patterns were similar between [patients] with RET+ and RET– MTC, indicating a need for broader education among physicians on considering more tailored treatment approaches for each group,” the poster’s authors said.

Read more about MTC treatment


Continue Reading

Patient data were provided by 153 physicians for 275 MTC patients as part of the Adelphi Thyroid Cancer Disease Specific Programme between July and December of 2020. A total of 79 patients (42%) were identified as having mutations in the RET proto-oncogene, out of the 186 MTC patients tested for it. Among the patients with RET mutations, 28% had a family history of thyroid cancer in comparison to 1% of MTC patients without RET mutations.

A similar percentage of patients with (47%) and without (41%) RET mutations received only targeted therapy (cabozantinib, vandetanib, or larotrectinib) as a first-line treatment. A total of 14 patients with RET mutations (18%) and 10 without them (9%) received hormone replacement therapy in addition to targeted therapy.

Fifteen patients with RET mutations and 23 patients without RET mutations discontinued first-line treatment, most commonly due to disease progression.

During locally advanced disease, 44% of patients with RET and 42% of patients without RET received surgical intervention. The most commonly received surgery among this group was total thyroidectomy (28 patients with RET and 36 patients without RET). A total of 15 patients with RET (19%) and 11 patients without (10%) had surgery during metastatic disease, with neck lymph node removal being the most common type.

Results of 67 patients (36 with RET and 31 without RET) with known dates of diagnosis and treatment initiation showed that the average time between the 2 events was 1.3 and 0.9 years, respectively (standard deviations [SD], 2.7 and 3.9 years). The mean ages of patients at data collection were 56.0 (SD, 19.9) and 62.0 (SD, 11.0) years for patients with RET and without RET, respectively.

Reference

Rider A, Hess LM, Puri T, et al. Characteristics and treatment [tx] patterns in patients [pts] with medullary thyroid cancer [MTC] with and without REarranged during Transfection [RET] mutations in Europe. Poster presented at: European Society for Medical Oncology (ESMO) Congress 2021; September 16, 2021; Virtual.